Ask AI

Capsule Summaries

Share

Program Content

Activities

MATTERHORN OS
Phase III MATTERHORN: Final OS and EFS by Pathologic Outcomes With Durvalumab + FLOT vs Placebo + FLOT in Resectable Gastric/GEJ Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 21, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly